Adimab, fidelity investments careers merrimack nh global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that six new partner programs entered clinical trials in 2017. This brings the total number of Adimab partner programs currently in clinical development to nine. Guy Van Meter, Senior Vice President of Business Development at Adimab.

Currently, Innovent Biologics is in Phase III clinical trials, which is the most advanced partner program based on the Adimab technology. In addition, Arsanis entered Phase II clinical trials with two Adimab antibodies. In 2017, Adimab partners exercised options to 15 commercial licenses to advance programs into preclinical development. These partners include Biogen, Celgene, Surface Oncology, The University of Texas MD Anderson Cancer Center, and others. Chief Executive Officer and Co-Founder of Adimab. As a platform company, we are not pursuing our own drug pipeline but have instead focused on the success of our partners. As such, we are thrilled to see the maturation of their programs and the early clinical impact of our work.

In vivo technologies can work well for many therapeutic targets. Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. Not only are we able to overcome many of those limitations but our engineering capabilities allow us to optimize any lead to become a best-in-class differentiated molecule. Under the terms of the agreement, Adimab will use its proprietary yeast-based discovery and optimization platform to identify fully human antibodies against multiple targets selected by BI. For each target, Adimab will grant BI the right to evaluate antibody panels generated during the collaboration for potential use in therapeutic products. Adimab will receive an undisclosed upfront payment, research fees, and delivery milestones. Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2017 it entered into agreements with seven new companies.

In addition, Adimab announced the expansion of 12 of its current partnerships and the achievement of 49 technical and development milestones across multiple collaborations. New alliances for 2017 include Moderna Therapeutics, Anokion Therapeutics, Mapp Biopharmaceuticals, Magenta Therapeutics, and Pionyr Immunotherapeutics, among others. Chief Executive Officer, President and Co-founder, Magenta Therapeutics. In July of 2017, Adimab expanded its partnership with Lilly through a Platform Transfer agreement, whereby Lilly’s San Diego site was enabled to use the Adimab Platform for IgG discovery, optimization, and bispecific engineering. Under the terms of the agreement Lilly is able to pursue any target of choice, with no restrictions on number of targets or disease areas. Lilly will also be able to access future improvements to the Adimab Platform. 2017 has been another great year for us.

We have generated multiple new collaborations, but more importantly we have seen several existing relationships expand significantly. Adimab, LLC, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into an agreement with Eli Lilly and Company to transfer the Adimab Platform to Lilly for the discovery and optimization of antibody-based drugs in all therapeutic areas. Thomas Bumol, Senior Vice President for Biotechnology and Immunology Research at Lilly. We believe that adding the Adimab Platform to our existing portfolio of capabilities is an important step for Lilly as we work to quickly and efficiently develop solutions that will make a positive impact on people’s lives. Adimab is a technology company that does not pursue its own internal pipeline. As such, we are very invested in the success of our collaborators. Under the terms of the agreement, Adimab will transfer and license its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York.